GHRP-6 (Peptide): The Ghrelin Mimetic, Potent GH Secretagogue, Cytoprotective Peptide

GHRP-6 is a synthetic growth hormone releasing hexapeptide that functions as a powerful ghrelin receptor agonist, inducing potent and pulsatile secretion of growth hormone while also exerting independent anti-inflammatory, cardioprotective, and neuroprotective effects that extend far beyond its endocrine actions.

---

1. Overview:

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It acts as a potent, selective agonist of the ghrelin receptor (GHS-R1a), also known as the growth hormone secretagogue receptor. Unlike GHRH which works through a distinct receptor, GHRP-6 acts directly on the pituitary and hypothalamus to stimulate growth hormone release in a pulsatile manner. Beyond its endocrine effects, GHRP-6 demonstrates broad cytoprotective properties via its interaction with CD36 and other signaling pathways, positioning it as a candidate for indications ranging from cachexia to stroke recovery .

---

2. Origin & Common Forms:

GHRP-6 is a fully synthetic peptide developed through rational drug design. It is not found in nature. It is available as a research chemical and has been developed as an investigational drug in several clinical contexts, particularly in Cuba for stroke and cardiac indications.

---

3. Common Supplemental Forms: Standard & Enhanced

· GHRP-6 Acetate (Research Grade): The standard synthetic form provided as a lyophilized powder for reconstitution. It is intended for laboratory research only and is not approved for human supplementation .

· Investigational Intravenous Formulation: Used in clinical trials as a sterile lyophilized preparation for intravenous administration, often combined with recombinant epidermal growth factor (EGF) .

---

4. Natural Origin:

· Synthetic Origin Only: GHRP-6 is entirely man-made. It contains D-amino acids (D-Trp) which are not found in natural proteins, rendering the peptide resistant to rapid enzymatic degradation and conferring enhanced stability and oral activity in preclinical models .

· Endogenous Analogue: It is a synthetic analog of met-enkephalin (an endogenous opioid peptide) but has been engineered to lack opioid activity. It acts as a mimetic of ghrelin, the natural hunger hormone .

---

5. Synthetic / Man-made:

· Process: GHRP-6 is manufactured via solid-phase peptide synthesis (SPPS). The sequence is assembled stepwise on a solid resin support, followed by cleavage, deprotection, and high-performance liquid chromatography (HPLC) purification .

---

6. Commercial Production:

· Precursors: Protected amino acids, resins, and coupling reagents for chemical synthesis; some GHRP-6 has been produced via recombinant technology in engineered yeast strains.

· Process: Large-scale solid-phase synthesis, purification to >98% purity, and lyophilization. Clinical-grade material is produced under Good Manufacturing Practice (GMP) conditions.

· Purity & Efficacy: Research grade is typically >95% pure, while clinical trial material meets pharmaceutical standards. Efficacy is measured by GH release in vivo and receptor binding assays .

---

7. Key Considerations:

The Ghrelin Receptor Agonist with Therapeutic Potential. GHRP-6 is a research chemical and not approved for consumer use. However, it has undergone Phase I and Phase II clinical trials for serious conditions. A 2024 clinical trial in acute ischemic stroke demonstrated that intravenous GHRP-6 (3.5 mg or 5 mg twice daily for 7 days) was safe and associated with favorable neurological outcomes at 6 months. The trial reported serious adverse event rates of 30% and 20% in treatment groups compared to 56.2% in controls, with only two events attributed to the study drug .

---

8. Structural Similarity:

A synthetic hexapeptide containing both L- and D-amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2). The presence of D-Trp at position 2 and D-Phe at position 5 confers resistance to proteolytic cleavage, significantly extending its half-life compared to natural peptides .

---

9. Biofriendliness:

· Utilization: Administered intravenously in clinical studies, reaching peak concentration rapidly. Subcutaneous injection is also effective in research settings. Oral bioavailability is low due to peptide nature.

· Pharmacokinetics: Exhibits a bi-phasic concentration profile with a rapid distribution phase followed by a slower elimination phase. Effects on GH release last approximately one hour, mimicking natural GH pulses .

· Metabolism: Degraded into small peptides and amino acids. The acetate salt form is stable when stored appropriately (powder at -20°C for up to 3 years) .

· Toxicity: A Phase I clinical trial in healthy volunteers escalated doses up to 400 µg/kg intravenously. Twenty-three adverse events were recorded across 12 individuals, all mild and non-serious. No serious adverse events were reported, establishing an acceptable safety profile .

---

10. Known Benefits (Clinically Supported):

· Growth Hormone Secretion: Potently stimulates GH release in both animals and humans through direct action on somatotrophs and hypothalamic pathways .

· Stroke Recovery (Phase II): In a randomized trial of acute ischemic stroke patients (n=36), EGF+GHRP-6 therapy resulted in favorable neurological outcomes (NIHSS), functional recovery (Barthel index, modified Rankin scale), and higher 6-month survival compared to standard care .

· Myocardial Infarction: Preclinical studies have shown GHRP-6 reduces infarct size and improves cardiac function when administered after ischemia-reperfusion injury .

· Gastrointestinal Protection: Demonstrated ability to inhibit the development of restraint stress-induced gastric lesions .

---

11. Purported Mechanisms:

· GHS-R1a Activation (Primary): Binds to the ghrelin receptor on pituitary somatotrophs and hypothalamic neurons, increasing intracellular calcium and triggering GH release .

· CD36 Receptor Binding: GHRP-6 also binds to CD36, a scavenger receptor involved in fatty acid transport and innate immunity, which may mediate some of its cytoprotective effects .

· PI3K/Akt Signaling: Activates the phosphatidylinositol 3-kinase/RAC-alpha serine/threonine-protein kinase pathway, promoting cell survival and inhibiting apoptosis .

· Anti-inflammatory: Blunts NF-κB expression and activation, reducing pro-inflammatory cytokine production.

· IGF-I Upregulation: Increases insulin-like growth factor I mRNA expression in tissues including the cerebellum, contributing to neuroprotection .

---

12. Other Possible Benefits Under Research:

· Neuroprotection: Shown to inhibit cerebellar cell death in aged rats via reduction of caspase 3 and 9 activation .

· Anti-fibrotic: Upregulates PPARγ while downregulating TGF-β, CTGF, and PDGF, suggesting potential in fibrotic diseases .

· Metabolic Effects: Reverses ovariectomy-induced effects on serum glucose and insulin levels .

· Sleep Promotion: In human studies, GHRP-6 administration increased stage 2 sleep duration .

---

13. Side Effects:

· From Clinical Trials (Mild): Sweating, bradycardia, transient flushing, and mild injection site reactions were noted as expected effects. In healthy volunteers, 23 mild adverse events occurred across 12 participants, none serious .

· Hormonal Effects: GHRP-6 stimulates ACTH and cortisol release in addition to GH, which may have metabolic implications .

· Serious: No treatment-related serious adverse events were reported in the Phase I healthy volunteer trial. In the stroke trial, serious adverse events occurred in treatment groups but were predominantly attributed to the underlying disease (stroke) rather than the study drug .

---

14. Dosing & How to Take:

· Clinical Trial Doses (Intravenous): 3.5 mg or 5.0 mg administered twice daily (12 hours apart) for 7 days. This was given in combination with 75 µg of recombinant EGF .

· Research Doses: Preclinical rodent studies typically use 32-600 µg/kg subcutaneously. In healthy volunteer studies, single intravenous doses ranged from 1 to 400 µg/kg .

· NOT FOR HUMAN CONSUMPTION: GHRP-6 is a research chemical not approved as a dietary supplement or medication outside of regulated clinical trials .

---

15. Tips to Optimize Benefits:

· Not a Supplement: GHRP-6 is not intended for self-administration. It remains an investigational drug in clinical development.

· Clinical Context: The most promising data support its use in acute ischemic stroke when administered within 12 hours of symptom onset, as demonstrated in the 2024 Phase II trial .

· Stability: For research use, store lyophilized powder at -20°C and reconstituted solutions at -80°C for long-term storage .

---

16. Not to Exceed / Warning / Interactions:

· For Research Use Only: All commercially available GHRP-6 is explicitly labeled "for research use only, not for human or veterinary use" .

· Stroke Trial Stopping Rules: The clinical trial protocol specified that if a serious adverse event rate >30% with high probability occurred in the 5.0 mg group, enrollment would stop. This did not occur .

· Reconstitution: For laboratory use, avoid inhalation, contact with eyes and skin. Use appropriate personal protective equipment including gloves and safety goggles .

---

17. LD50 & Safety:

· Acute Toxicity (LD50): Not formally established for humans. Preclinical studies indicate a wide safety margin .

· Human Safety: A dose-escalation Phase I trial in 18 healthy volunteers scaled to 400 µg/kg intravenously without reaching a maximum tolerated dose. An acceptable safety profile was established with no serious adverse events .

· Hazard Classification: The pure peptide is not classified as a hazardous substance under GHS criteria .

---

18. Consumer Guidance:

· Label Literacy: GHRP-6 will be labeled as "GHRP-6 Acetate" or "Growth Hormone Releasing Peptide-6." Legitimate suppliers include a clear "For Research Use Only" disclaimer and provide a Safety Data Sheet .

· Quality Assurance: For research purposes, verify purity (>95%) via HPLC and mass spectrometry data provided by the supplier. Store as recommended to maintain stability.

· Manage Expectations: GHRP-6 is an investigational drug with human safety data from controlled clinical trials, but it is not approved for consumer use. Its effects on GH release are potent but transient (approximately one hour). The most clinically promising data relate to ischemic stroke recovery, not athletic performance enhancement or anti-aging, despite unsubstantiated claims in the bodybuilding community. Do not purchase or use for self-medication .